March 24, 2015, marks a historic date for vitreoretinal surgery in Italy: Dr. Alberto Bellone performed his first 27-gauge (27G) mini-invasive vitrectomy since the device became available and authorized for commercial use. This surgery marked a turning point, introducing a gentler, less traumatic technique with a faster recovery time compared to previous methods.
The 27G vitrectomy revolutionized the surgical approach to vitreoretinal diseases, offering numerous advantages over traditional techniques with larger gauges (23G and 25G). By using smaller diameter instruments, it was possible to significantly reduce tissue trauma, improve postoperative comfort, and achieve better visual outcomes with fewer complications.
Today, ten years later, this technique has become the gold standard in advanced vitreoretinal surgery. In this article, we review the evolution of the 27G vitrectomy, analyzing its impact on treated patients and the future prospects of this technological innovation.
The Impact of 27G Vitrectomy in 10 Years
From 2015 to today, the 27G vitrectomy has found an increasingly wide application in the treatment of various retinal diseases, including macular pucker, macular holes, and vitreous hemorrhages. The ability to operate with less invasive instruments has reduced postoperative discomfort for patients and improved visual prognosis.
One of the most significant aspects of the adoption of the 27G vitrectomy has been the improvement in both functional and anatomical parameters of patients. Data collected over the past ten years show a significant increase in postoperative visual quality, with an average improvement in visual acuity within three months of surgery and further stabilization at six months. Additionally, OCT parameters have shown a reduction in central retinal thickness (CST) and vitreoretinal volume (CUBEV), confirming the procedure’s effectiveness in restoring retinal architecture.
At the same time, the wider adoption of the technique has led to improvements in surgical instruments and associated technologies. The refinement of 27G forceps and vitrectors has allowed for greater precision in intraocular maneuvers, reducing the risk of complications and improving clinical outcomes. Furthermore, the enhancement of anesthesiology techniques and reduced surgical times have made the procedure even safer and more effective.
Clinically, the success of the 27G vitrectomy has sparked growing interest in the scientific community, with numerous studies confirming its benefits over traditional techniques. Ongoing research and development in this field promise further advances that could make vitreoretinal surgery even less invasive and more efficient in the coming years.
Evolution of the Technique and New Prospects
Over the past ten years, the 27G vitrectomy has continued to evolve due to constant improvements in instrumentation and the adoption of new technologies. The ophthalmic industry has made significant investments in developing more efficient vitrectors, capable of ensuring better cutting performance and improved vitreous aspiration, further reducing surgical times.
Another notable innovation is the introduction of advanced fluidics and new intraoperative illumination systems. These improvements have allowed for optimal visibility during the procedure, facilitating the management of more delicate retinal structures and enhancing the safety of the procedure.
Techniques for closing micro-incisions have also evolved, minimizing the risk of postoperative complications. Today, in many cases, 27G incisions are self-sealing, eliminating the need for sutures and contributing to faster patient recovery.
Looking to the future, research is focusing on new approaches to vitreoretinal surgery, including the use of artificial intelligence to support surgical planning and postoperative monitoring. Additionally, the development of surgical robots could further refine operative techniques, increasing precision and minimizing human error.
The evolution of 27G vitrectomy represents an example of how ophthalmic surgery is in constant transformation, with the aim of offering safer and more effective treatments. The next challenge will be to further integrate new technologies to improve the patient experience and optimize clinical outcomes.
